Evidence map›Paper›PMID 37213481›Full record

ArticleAdvances in radiation oncology

Computational Analysis of Tumor Treating Fields for Non-Small Cell Lung Cancer in Full Thoracic Models.

Edwin Lok, Olivia Liang, Talbia Malik, Eric T Wong

2 registry-linked trialsAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02831959 phase3completednot on this map

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

TypeinterventionalSponsorNovoCure GmbHRan2016 to 2024Enrolled298ConditionsBrain Metastases From Non-small Cell Lung Cancer (NSCLC)ArmsNovoTTF-200M device, Best Standard of Care
NCT02973789 phase3completednot on this map

LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure

TypeinterventionalSponsorNovoCure GmbHRan2016 to 2024Enrolled291ConditionsNonsmall Cell Lung Cancer, NSCLCArmsNovoTTF-200T, Immune checkpoint inhibitors or docetaxel
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Hydrogel and scalp/skin conductivities impact dose from tumor treating fields.Frontiers in bioengineering and biotechnology · 2025
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Edwin LokBrain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Olivia LiangBrain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Talbia MalikBrain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Eric T WongBrain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center, Boston, Massachusetts.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Tumor Treating Fields (TTFields) are alternating electric fields at 150 to 200 kHz that exert their anticancer effect by destroying tumor cells when they undergo mitosis. TTFields are currently being tested in patients with non-small cell lung cancer with advanced disease (NCT02973789) and those with brain metastasis (NCT02831959). However, the distribution of these fields within the thoracic compartment remains poorly understood. Methods and Materials: Using positron emission tomography-computed tomography image data sets obtained from a series of 4 patients with poorly differentiated adenocarcinoma, the positron emission tomography-positive gross tumor volume (GTV), clinical target volume (CTV), and structures from the chest surface to the intrathoracic compartment were manually segmented, followed by 3-dimensional physics simulation and computational modeling using finite element analysis. Electric field-volume histograms, specific absorption rate-volume histograms, and current density-volume histograms were generated to produce plan quality metrics (95%, 50%, and 5% volumes) for quantitative comparisons between models. Results: Unlike other organs in the body, the lungs have a large volume of air, which has a very low electric conductivity value. Our comprehensive and individualized models demonstrated heterogeneity in electric field penetration to the GTVs with differences upwards of 200% and yielded a diverse range of TTFields distributions. Target contact with the conductive pleura intensified TTFields at the GTV and CTV. Furthermore, in a sensitivity analysis, varying electric conductivity and mass density of the CTV altered TTFields coverage to both the CTV and GTV. Conclusions: Personalized modeling is important to accurately estimate target coverage at the tumor volumes and surrounding normal tissue structures in the thorax.

Identifiers

PMID37213481
PMCPMC10196273

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.